Abstract
INTRODUCTION
Diabetic foot ulcers (DFUs) are among the most common complications of diabetes mellitus with a lifetime incidence of up to 15% among the diabetic population [1] . Studies have shown that up to 80% of patients with DFUs suffer from both limb ischemia and peripheral neuropathy simultaneously [2, 3] . These conditions further delay healing of DFUs, predisposing to higher rates of complications such as cellulitis and osteomyelitis [4] . In
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October 15, 2018|Volume 9|Issue 10| WJD|www.wjgnet.com Hirase T et al . Platelet-rich plasma for diabetic foot ulcers spite of the high prevalence and morbidity associated with DFUs, current treatment options are limited. Current standard management consists of surgical debridement followed by frequent dressing changes with tight infection and glycemic control. Despite this comprehensive approach, complication and amputation rates remain high [5] .
In recent years, the use of autologous platelet-rich plasma (PRP) has emerged as an adjunctive method for treating DFUs [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . PRP is derived from centrifugation of whole blood, which separates into 3 layers: platelet poor plasma, platelet rich plasma, and red blood cells. Contained within these platelets are a number of hemodynamically active proteins that aid in the natural process of wound healing. Specifically, the platelet alphagranules contain several of these molecules, including: platelet derived growth factor (PDGF), TGF-β, vascular endothelial growth factor (VEGF), epithelial growth factor (EGF), fibrinogen, fibronectin, and vitronectin [17] [18] [19] . In addition, platelet delta granules contain serotonin, histamine, dopamine, calcium, and adenosine, which act in tandem with the aforementioned growth factors to regulate wound healing [20] . With increasing knowledge about the pathophysiology of refractory DFUs, alterations to the local microenvironment with PRP could play an important role in mitigating the morbidity associated with these chronic wounds.
Current studies evaluating the outcomes of topical autologous PRP on diabetic foot ulcers are limited to small randomized controlled studies and case reports. Given that there are numerous confounding variables involved with PRP use, there has been significant challenge in generating standardized protocols for patient use. Thus, the purpose of this investigation was to summarize the clinical outcomes of the topical application of autologous PRP among patients with DFUs and to determine if the method results in statistically superior outcomes compared to patients receiving conventional wound care. The authors hypothesized that the procedure results in statistically superior outcomes compared to patients receiving conventional wound care with low complication rates.
MATERIALS AND METHODS
A systematic review was registered with PROSPERO on March 9, 2017 (ID: CRD42018090780). Preferred Reporting Items for Systematic Reviews and Metaanalyses (PRISMA) guidelines were followed [21] . Inclusion criteria consisted of Level Ⅰ-Ⅳ [via Oxford Centre for Evidence Based Medicine (CEBM)] therapeutic studies that investigated outcomes of topical applications of autologous PRP for diabetic foot ulcers among adult human patients [22] . Studies that included non-diabetic etiology of foot ulcers and use of non-autologous PRP were excluded. Cadaveric studies, basic science and animal studies, diagnostic studies, economic studies, prognostic studies, Level Ⅴ evidence expert opinion, letters to editors, and review articles were excluded.
Studies published in non-English languages were not excluded but were unidentified in the medical databases. In the event of different studies with duplicate subject populations, the study with the longer follow-up, higher level of evidence, greater number of subjects, or greater clarity of methods and results was included. The authors conducted separate searches of the following medical databases: MEDLINE, Web of Science, and Cochrane Central Register of Controlled Trials databases. Under the PROSPERO registration, similar prior systematic reviews and meta-analyses were sought and none were identified. The searches were performed on March 8, 2017 . The search terms used were "platelet rich plasma", "diabetes", "ulcers", and "wound". The search results were reviewed for duplicates and the inclusion criteria to determine articles that were included in the final analysis ( Figure 1) .
Two authors independently reviewed all articles. The study design, patient populations, and procedure technique were first identified. A weighted mean of the demographics (No. of patients, age, % female gender, duration of diabetes, duration of ulcer, HbA1c, and ulcer area) between PRP group vs controls were compared using two-sample z-tests using p-value of less than 0.05 for significance. All reported outcome scores and complication rates were analyzed. The levels of evidence were then assigned based on the Oxford Centre for Evidence Based Medicine [22] . Study methodological quality was analyzed using the Modified Coleman Methodology Score (MCMS) [23] . The overall Strength-ofRecommendation Taxonomy (SORT) score was B and Grading of Recommendations Assessment, Development and Evaluation (GRADE) score was C [24, 25] . Study heterogeneity and a mostly non-comparative nature of evidence precluded meta-analysis. Thus, a best-evidence synthesis was used instead [26] . Only the outcome measurements used by more than 50% of the studies were included in the data synthesis to increase power of the measurement over that of individual studies. A weighted mean of healing rate per week between PRP group vs controls were compared using two-sample z-tests using p-value of less than 0.05 for significance.
RESULTS
One thousand two hundred and seventeen articles were screened ( Figure 1 ). Eleven articles were included in the analysis (Table 1 ) [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . Six articles were level Ⅱ evidence, four were level Ⅲ, and one article was level Ⅳ. According to MCMS, three articles were good (scores between 70 to 84), seven articles were fair (scores between 55 to 69), and one article was poor (scores less than 55). The mean MCMS was 61.8 ± 7.3. There were 465 patients analyzed. 322 patients were under the PRP group and 126 patients were under the control group (standard dressing changes ± placebo gel). There were 206 males and 87 females (29 unidentified) in the PRP group and 72 males and 39 females (15 unidentified) in the control group (p = 0.407). Mean follow-up was 10.4 ± 3.1 wk. The mean ages were 58.4 ± 7.2 years and 58.7 ± 5.9 years under the PRP and control groups, respectively (p = 0.678). The mean HbA1c were 7.94 ± 1.30 and 8.74 ± 1.08 under the PRP and control groups, respectively (p < 0.001). The mean baseline ulcer areas were 7.7 ± 9.3 cm 2 and 4.6 ± 6.6 cm 2 under the PRP and control groups,
Most studies prepared PRP through a single or double spinning approach and utilized Thrombin, CaCl2, and/or calcium gluconate as activator (Table 2) . Four studies reported the amount of PRP gel applied to the wound, and two studies reported platelet concentration. Only one study reported WBC count in the final PRP prepared.
Eight studies assessed the time to > 90% ulcer area healing and seven studies assessed healing rate per week (Table 3 ). Both outcome measures were included in the best evidence synthesis. Other outcome measures included percent of ulcer completely healed at 8 and/or 12 wk follow-up (6 of 11 studies), comparison of ulcer area at baseline and at final follow-up (2 of 11 studies), Resvech 2.0 measurement score at baseline and at final follow-up (1 of 11 studies), and percent of wound length/width/depth decrease at final follow-up (1 of 11 studies).
Mean heal time to > 90% of the original ulcer area was 7.8 ± 2.7 wk and 8.3 ± 3.7 wk for patients in the PRP group and control groups, respectively (Table 4 ; p = 0.115).
Mean healing rate was significantly faster with PRP application compared to controls (0.68 
DISCUSSION
It was determined that the topical application of PRP for DFUs resulted in statistically superior healing rate compared to patients receiving conventional wound care with low complication rates. This confirmed the authors' hypothesis that patients receiving this treatment results in significantly superior outcomes compared to patients receiving
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Saldalam-acchia et al [13] 2004 Motolese et al [14] 2015 Shan et al [15] 2013 Kontopodis et al [16] 2016 PRP spinning approach compared to conventional treatment methods with lower complication rates. However, further higher quality studies with randomized controlled trials are necessary to justify the use of PRP over more cost-effective treatment methods. There are several limitations among the studies included in this review. Five of the 11 articles were levels Ⅲ or Ⅳ evidence, which limits the strength of the results. Only one of the studies used a double-blinded approach producing potential bias. The average study methodological quality as assessed by the MCMS was fair. Assimilation of heterogeneous low methodological quality studies with healing rates is a significant limitation. However, the authors minimized this as much as possible with strict study eligibility and inclusion criteria, despite the level Ⅲ and Ⅳ evidence nature of the studies. Furthermore, the heterogeneity of outcome measures used among the studies limited the data analysis to two outcome measures. Another limitation of this review is that most reviewed studies did not include relevant baseline comorbidities including preexisting peripheral arterial obstructive disease nor baseline home medications and were unable to be compared in this review. Future studies can improve through designing more prospective comparative trials, increasing study sizes, and standardizing clinical outcome measures such as healing rates, percentage of ulcers completely healed, and ulcer area at baseline and final follow-up. Another possible limitation of this review is that other relevant studies on this topic could have been excluded, despite conducting a systematic search.
In conclusion, topical application of autologous PRP for DFUs results in statistically superior healing rates compared to controls with lower complication rates. Further randomized controlled studies that show clinical outcome improvement in multiple parameters are necessary to evaluate the true efficacy of this treatment.
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Research background
Diabetic foot ulcers (DFUs) are among the most common complications of diabetes mellitus but current treatment options are limited. Current standard management consists of surgical debridement followed by frequent dressing changes with tight infection and glycemic control. In recent years, the use of autologous platelet-rich plasma (PRP) has emerged as an adjunctive method for treating DFUs.
Research motivation
Because current studies evaluating the outcomes of topical autologous PRP on diabetic foot ulcers are limited to small randomized controlled studies and case reports. Given that there are numerous confounding variables involved with PRP
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use, there has been significant challenge in generating standardized protocols for patient use.
Research objectives
The objective was to determine if topical application of platelet-rich plasma (PRP) to diabetic foot ulcers (DFUs) results in superior healing rates. The significance of realizing this objective combined with future research consisting of further randomized controlled studies will help evaluate the true efficacy of this treatment.
Research methods
This review was registered with PROSPERO and performed using PRISMA guidelines. Level Ⅰ-Ⅳ investigations of topical PRP application in DFUs were sought in multiple databases, i.e., MEDLINE, Web of Science, and Cochrane Central Register of Controlled Trials. The search terms used were "platelet rich plasma", "diabetes", "ulcers", and "wound". The Modified Coleman Methodology Score (MCMS) was used to analyze study methodological quality.
Research results
One thousand two hundred and seventeen articles were screened, eleven articles were analyzed, six articles were level Ⅱ evidence, four were level Ⅲ, and one article was level Ⅳ. The mean MCMS was 61.8 ± 7.3. Healing rate was significantly faster with PRP application compared to controls (0.68 ± 0.56 cm 2 /wk vs 0.39 ± 0.09 cm 2 /wk; p < 0.001). Mean heal time to > 90% of the original ulcer area for patients in the PRP group was significantly lower with control groups (7.8 ± 2.7 wk vs 8.3 ± 3.7 wk, p = 0.115). There were significantly lower adverse effects reported with PRP application compared to controls (7 wound infections, 1 contact dermatitis vs 14 wound infections, 1 maceration; p < 0.001).
Research conclusions
We find that the topical application of PRP for DFUs results in statistically superior healing rates and lower complication rates compared to controls. This study proposes the new theory that the use of PRP is a superior option to treating DFUs than the current standard of care. A new hypothesis that may be proposed from this study is that the use of PRP results in clinical outcome improvement in multiple parameters. Combining the findings within this study with future research consisting of further randomized controlled studies that show clinical outcome improvement in multiple parameters will provide adequate evaluation of the true efficacy of this treatment.
Research perspectives
The assimilation of heterogeneous studies allowed the development of a high quality systematic review that analyzes two outcome measures. Future studies can improve through designing more prospective comparative trials, increasing study sizes, and standardizing clinical outcome measures such as healing rates, percentage of ulcers completely healed, and ulcer area at baseline and final follow-up. Table 4 Average study outcome measures included in best evidence synthesis PRP: Platelet-rich plasma.
